In vitro study details the increased performance and potential of CPSI’s Supercritical Nitrogen cryoablation device for the epicardial based ablation of cardiac tissue

OWEGO, NY – CPSI Biotech announced today the publication of a peer-reviewed article detailing the enhanced performance CPSI’s next generation supercritical nitrogen (SCN) cryoablation device and its potential application in the treatment of cardiac arrhythmias. The study, titled “Evaluation of a New Epicardial Cryoablation System for the Treatment of Cardiac Tachyarrhythmias”, published as an open access article in the journal Trends in Medicine (February 2, 2018, accessible free of charge at: http://www.oatext.com/evaluation-of-a-new-epicardial-cryoablation-system-for-the-treatment-of-cardiac-tachyarrhythmias.php), was a multi-institutional collaboration between researchers from CPSI and Binghamton University.

The article details developments in CPSI’s cardiac cryoablation technology platform. The study investigated the performance of the patented Supercritical Nitrogen (SCN) cryoablation system and epicardial cryoablation probe developed by CPSI. The studies, conducted using a series of heat loaded engineering and tissue models, demonstrated the ability of the system to quickly and effectively deliver an ablative dose. Commenting on the study, Dr. John M. Baust (CPSI President and Lead Scientist) stated “We have been working on a series of a next generation cryoablation devices and probes for targeting various cardiac arrhythmias for a number of years. These activities have resulted in the development of a platform of new ablation probes and catheters, the ICEolate platform, designed to support ablation of cardiac tissue using either a epicardial or endocardial approach. This specific study focused on evaluations of the epicardial cryoprobe technology. The results demonstrate that the SCN system is able to generate ablative power several fold greater than today’s commercial cryoablation systems and as such deliver a ablative dose in less than one minute in many cases.”

This study was conducted as part of CPSI’s ongoing research and technology development program which involves the development of a next generation cryoablation devices and approaches for the treatment of various disease states. Ongoing efforts continue to build upon this success and are focusing on continued development, optimization and testing of these new devices. Speaking to the broader device development program at CPSI, Baust added “while this study focused on our prototype epicardial cardiac probe, we are also actively developing linear and balloon tipped catheter technologies as part of the ICEolate platform to support endocardial based procedures. The power of the patented cryoablation engines that CPSI’s engineers have developed has opened a number of doors for advanced treatment for various diseases. We are excited to take the next steps with this technology.” With development underway, CPSI is poised to embark down the commercialization path. To this end, Baust commented “We are actively seeking investors and partners through a variety of mechanisms to join our team to bring this potentially lifesaving technology platform to the market.”

Click Here to read the full Press Release: New Cryoablation Device Targets Enhanced Treatment of Cardiac Arrhythmias 

View other CPSI Biotech news and recent patent announcements

post

SmartThaw Presentation Given at Cryo2016

CPSI researchers present a scientific poster on the SmartThaw™ cell thawing system.

OWEGO, NY — CPSI Biotech scientists just returned from presenting at the Society for Cryobiology Annual Meeting (Cryo2016) in Ottawa, CA (July 24-27). CPSI’s involvement included a scientific poster presentation and demonstration of CPSI’s new SmartThaw™ device designed to improve the thawing process of frozen cell and tissue products.

This scientific study on SmartThaw™ conducted by a team of researchers from CPSI and led by Dr. Kristi Snyder (Director of Operations and Principal Scientist) and Kimberly Santucci (Research Scientist). “SmartThaw™ System is a new device for controlled and rapid dry thawing of cryopreserved (frozen) samples and products. This study demonstrated that sample thawing with SmartThaw™ improves processing of frozen products while also providing equivalent, and in several cases, improved sample viability post-thaw” stated Ms. Santucci. Speaking to the technology, Dr. Snyder stated “We introduced the prototype system this spring and have been collecting end-user feedback and input for final design and performance focus. These insights have aided in the final design engineering which is now in process. As a result of these ongoing activities, we are targeting commercial launch in late Q3 2016.”

The poster titled “Assessment of SmartThaw™: A novel dry thawing system for cryopreserved cell products” focused on the improved processing and outcome that can be obtained using SmartThaw™. The poster highlighted studies conducted on CHO, PC-3, human endothelial, and mesenchymal stem cells.

Click here to read the full press release: CPSI researchers present a scientific poster on the SmartThaw™ cell thawing system.

View the Poster Presented at the Society for Cryobiology conference: Cryo 2016 Smart Thaw Poster

View other CPSI Biotech news and recent patent announcements

Article published in BioProcessing Journal details how CPSI Biotech’s novel SmartThaw™ dry thawing device could revolutionize frozen sample thawing

OWEGO, NY – A peer-reviewed research article detailing the development of CPSI’s SmartThaw™ device was published in this month’s issue of BioProcessing Journal (Volume 15, Number 1; pages 30-41).  The manuscript, titled Development and Assessment of a Novel Device for the Controlled Dry Thawing of Cryopreserved Cell Products, focuses on comparative evaluations between SmartThaw™ and water bath thawing (the gold standard) using human mesenchymal stem cell (hMSC) and prostate cancer (PC-3) cell cultures and demonstrates the improvement in sample processing and quality obtained using SmartThaw™.

Click here to read the full press release: SmartThaw™ Offers a New Standard in Thawing of Cryopreserved Products

View other CPSI Biotech news and recent patent announcements